Cryptosporidium parvum has an active hypusine biosynthesis pathway

Area of Science:

• Parasitology
• Molecular Biology
• Biochemistry

Background:

• Cryptosporidium parvum causes significant diarrheal disease, especially in immunocompromised individuals and children.
• No fully effective treatments are currently available for cryptosporidiosis.
• Hypusination of eIF5A, a process involving deoxyhypusine synthase (DHS), is crucial for cell proliferation.

Purpose of the Study:

• To identify and characterize the Cryptosporidium parvum deoxyhypusine synthase (CpDHS) enzyme.
• To investigate CpDHS as a potential drug target for treating cryptosporidiosis.
• To explore the mechanism, structure, and inhibition profile of CpDHS.

Main Methods:

• Identification and cloning of the CpDHS gene.
• Recombinant protein expression, purification, and kinetic analysis.
• Sequence analysis, structural modeling, and phylogenetic studies.
• In vitro inhibition assays using N(1)-guanyl-1,7-diaminoheptane (GC7).

Main Results:

• A single gene encoding CpDHS was identified, with the recombinant protein purified.
• CpDHS shares conserved functional residues with human DHS, indicating potential for targeted inhibition.
• Phylogenetic analysis places CpDHS closer to apicomplexan DHS than kinetoplastid DHS.
• The DHS inhibitor GC7 effectively inhibited C. parvum infection and growth in HCT-8 cells.

Conclusions:

• CpDHS is a viable drug target for treating Cryptosporidium parvum infections.
• Inhibiting CpDHS offers a promising therapeutic strategy against cryptosporidiosis.
• Further research into CpDHS inhibitors could lead to effective treatments for this disease.